Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VEEV 
Veeva Systems Inc Class A (VEEV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VEEV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $320.62
1 Year Target Price $320.62
| 12 | Strong Buy |
| 7 | Buy |
| 11 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.98% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 47.98B USD | Price to earnings Ratio 58.5 | 1Y Target Price 320.62 |
Price to earnings Ratio 58.5 | 1Y Target Price 320.62 | ||
Volume (30-day avg) 32 | Beta 0.98 | 52 Weeks Range 201.54 - 310.50 | Updated Date 10/17/2025 |
52 Weeks Range 201.54 - 310.50 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.29% | Operating Margin (TTM) 28.71% |
Management Effectiveness
Return on Assets (TTM) 7.24% | Return on Equity (TTM) 13.7% |
Valuation
Trailing PE 58.5 | Forward PE 35.34 | Enterprise Value 42983626230 | Price to Sales(TTM) 16.16 |
Enterprise Value 42983626230 | Price to Sales(TTM) 16.16 | ||
Enterprise Value to Revenue 14.48 | Enterprise Value to EBITDA 51.22 | Shares Outstanding 163908013 | Shares Floating 150420023 |
Shares Outstanding 163908013 | Shares Floating 150420023 | ||
Percent Insiders 8.52 | Percent Institutions 88.62 |
Upturn AI SWOT
Veeva Systems Inc Class A
Company Overview
History and Background
Veeva Systems was founded in 2007 by Peter Gassner and Matt Wallach. It focuses on cloud-based software solutions for the global life sciences industry. Veeva has grown significantly, expanding its product offerings and customer base.
Core Business Areas
- Veeva Commercial Cloud: Provides CRM, content management, multichannel marketing, and data solutions for commercial teams in life sciences.
- Veeva Vault: Offers a unified cloud platform for managing content and data across research & development, quality, and regulatory functions in life sciences.
Leadership and Structure
Peter Gassner is the Founder and Chairman of the Board. The company operates with a typical hierarchical structure, with various functional departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Veeva CRM: Cloud-based CRM for pharmaceutical sales teams. Veeva claims to be the market leader in this segment. Competitors include Salesforce Health Cloud and Microsoft Dynamics 365.
- Veeva Vault EDC: Electronic Data Capture system for clinical trials. It's used for data management. Competitors include Medidata Rave and Oracle Clinical One.
- Veeva Network: Provides patient data and key opinion leader (KOL) data. Competitors include IQVIA and Definitive Healthcare.
Market Dynamics
Industry Overview
The life sciences industry is increasingly adopting cloud-based solutions for CRM, content management, and regulatory compliance. The market is driven by the need for improved efficiency, data management, and compliance.
Positioning
Veeva is positioned as a leading provider of cloud-based solutions specifically tailored for the life sciences industry, giving them a competitive advantage by focusing on the niche market.
Total Addressable Market (TAM)
Estimates put the TAM at tens of billions of dollars. Veeva is positioned to capture a significant portion of the market as the industry continues to digitize.
Upturn SWOT Analysis
Strengths
- Industry expertise
- Cloud-based solutions
- Strong customer relationships
- Market leadership in specific segments
- Scalable platform
Weaknesses
- High dependency on the life sciences industry
- Premium pricing may deter some customers
- Potential vendor lock-in for customers
- Can be expensive compared to other CRMs
Opportunities
- Expanding product offerings
- Geographic expansion
- Partnerships with other technology providers
- Increased adoption of cloud solutions in life sciences
- Further development of AI driven solutions
Threats
- Competition from larger technology companies
- Economic downturn impacting the life sciences industry
- Changes in regulatory requirements
- Emergence of disruptive technologies
- Data security breaches
Competitors and Market Share
Key Competitors
- CRM
- ORCL
- ADSK
- MEDP
Competitive Landscape
Veeva's strength lies in its industry-specific expertise, but it faces competition from larger, more diversified technology companies.
Major Acquisitions
Crossix
- Year: 2019
- Acquisition Price (USD millions): 430
- Strategic Rationale: Enhanced Veeva's data and analytics capabilities for commercial operations.
Growth Trajectory and Initiatives
Historical Growth: Veeva has experienced strong revenue growth due to increased adoption of its cloud-based solutions.
Future Projections: Analysts project continued growth for Veeva, driven by demand for cloud solutions in the life sciences industry.
Recent Initiatives: Veeva has been expanding its product offerings and investing in research and development, including AI.
Summary
Veeva is a strong company with a leading position in cloud solutions for the life sciences industry. Its industry focus and strong customer relationships are key advantages. Challenges include competition from larger tech companies and dependency on the life sciences sector. They must look out for potential disruptions in the sector from increased competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- SEC Filings
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary. Financial data may not be exact and it is advised to see SEC filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veeva Systems Inc Class A
Exchange NYSE | Headquaters Pleasanton, CA, United States | ||
IPO Launch date 2013-10-16 | Founder, CEO & Director Mr. Peter P. Gassner | ||
Sector Healthcare | Industry Health Information Services | Full time employees 7291 | Website https://www.veeva.com |
Full time employees 7291 | Website https://www.veeva.com | ||
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud consisting of Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; and Veeva RIM that provides regulatory information management capabilities; as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.